title: Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.
abstract: OBJECTIVE
  • Germline CAG repeat polymorphisms in the androgen receptor (AR-CAG) have been shown to influence the activity of the AR. • The purpose of the present study was to determine if AR-CAG repeat length correlates with time to progression on androgen deprivation therapy (ADT).
  
  
  METHODS
  • Germline AR-CAG repeat lengths were determined in a cohort of 480 patients with recurrent or metastatic prostate cancer treated at a single tertiary care institution and correlated to time to progression (TTP) and overall survival.
  
  
  RESULTS
  • There was no significant correlation between differences in the AR-CAG repeat lengths and TTP or overall survival in patients with prostate cancer receiving ADT. • AR-CAG repeat lengths did not significantly correlate with age, prostate-specific antigen (PSA), Gleason score or clinical stage at diagnosis. • In patients with metastatic disease, longer AR-CAG repeat lengths (>23 vs ≤23) were associated with a longer TTP on ADT, but this finding was of borderline significance (median TTP 18.3 vs 15.5 months, P = 0.09; adjusted HR = 0.76, 95% confidence interval = 0.54-1.09).
  
  
  CONCLUSIONS
  • This is the largest published study to date investigating the association of germline AR-CAG repeat lengths and efficacy of ADT in prostate cancer. • Germline AR-CAG repeat lengths do not predict response to ADT.
authors.affiliation: Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: Dipika
authors.initials: D
authors.lastname: Misra
authors.forename: Wanling
authors.initials: W
authors.lastname: Xie
authors.forename: Meredith M
authors.initials: MM
authors.lastname: Regan
authors.forename: Robert W
authors.initials: RW
authors.lastname: Ross
authors.forename: Gwo-shu
authors.initials: GS
authors.lastname: Lee
authors.forename: Doris
authors.initials: D
authors.lastname: Germain
authors.forename: Philip W
authors.initials: PW
authors.lastname: Kantoff
authors.forename: William K
authors.initials: WK
authors.lastname: Oh
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D005854:Germ Cells; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000628:therapy*; D011944:Receptors, Androgen / Q000235:genetics*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D011944:Receptors, Androgen; D007987:Gonadotropin-Releasing Hormone